AngioDynamics Reports Strong Q3 Results, Raises Full-Year Guidance for Third Consecutive Quarter

summarizeSummary

AngioDynamics announced strong Q3 FY26 results with significant Med Tech growth and raised its full-year guidance across key metrics for the third consecutive quarter, despite a minor adjustment to cash flow expectations.

check_boxKey Events

• Strong Q3 Financial Performance

  AngioDynamics reported Q3 FY26 net sales of $78.4 million, an 8.9% pro forma increase year-over-year, driven by 19.0% growth in its Med Tech segment. Adjusted EBITDA improved to $1.8 million from $1.3 million in the prior-year quarter.

• Raised Full-Year FY26 Guidance

  For the third consecutive quarter, the company increased its full-year FY26 guidance for net sales (to $313.5-$315.5M), Med Tech net sales growth (to 15%-17%), Adjusted EBITDA (to $10.0-$12.0M), and Adjusted EPS (to ($0.30)-($0.23)).

• Solid Balance Sheet

  The company ended the quarter with $37.8 million in cash and maintains a debt-free balance sheet, providing financial flexibility.

• Cash Flow Impact from Inventory Build

  Full-year operating cash flow is now expected to be slightly negative due to a proactive $3.0-$5.0 million inventory build in Q4 to mitigate potential supply chain disruptions, though the long-term positive cash generation pathway remains unchanged.

auto_awesomeAnalysis

AngioDynamics reported strong fiscal Q3 2026 financial results, highlighted by an 8.9% increase in pro forma net sales to $78.4 million and robust 19.0% growth in its higher-margin Med Tech segment. This performance led management to raise its full-year FY 2026 guidance for net sales, Med Tech growth, Med Device growth, Adjusted EBITDA, and Adjusted EPS for the third consecutive quarter, signaling sustained operational momentum. While the company anticipates slightly negative full-year operating cash flow due to a proactive inventory build, it maintains a debt-free balance sheet with $37.8 million in cash, underscoring financial stability. The consistent outperformance and upward revision of outlook suggest a positive trajectory for the company's strategic initiatives.